Introduction
============

The proarrhythmic effects of cardiac and non-cardiac drugs have comprised a major drug safety issue for the past 20 years ([@B33]; [@B5]; [@B19]). The electrocardiogram (ECG) is an effective means of determining whether a drug is proarrhythmic. Under certain conditions, prolongation of the QT interval increases the risk of developing Torsades de pointes (TdP), which can lead to sudden cardiac death ([@B26]). The Comprehensive *in vitro* Proarrhythmia Assay (CiPA) was recently proposed to improve the accuracy of drug safety prediction during preclinical and clinical development ([@B30]; [@B31]). The CiPA comprises *in silico* simulation of several ion-channel assays and ECG studies to identify biomarkers of false-positive results of single hERG channel assays and thorough QT (TQT) studies ([@B4]) performed according to the International Council for Harmonisation (ICH) S7B and E14 guidelines. There have been a large number of studies that investigated the effect of drugs on ECG using in silicon three-dimensional (3D) heart model. [@B32] examined the effect of the block of ion channels on ECG parameters. [@B21] generated an arrhythmic hazard map under multiple ion channel blocks. [@B25] investigated the critical drug concentration which induced torsade de pointes. [@B23] performed sensitivity analysis of JT~peak~ and T-wave morphology parameters.

In this study, we further examined the utility of 3D ECG simulation in evaluating drug safety by simulating ECG at relatively high concentrations of drugs using realistic models of the ventricles and torso. We tested dofetilide, bepridil, cisapride, ranolazine, verapamil, mexiletine, and diltiazem using the 3D model and examined the morphologies of the simulated ECG data according to drug concentration. Dofetilide, bepridil, and cisapride are high or intermediate-proarrhythmic-risk drug that prolongs the QT by blocking hERG. Verapamil and ranolazine are "false positive" low-proarrhythmic-risk drugs; they induce prolonged QT by hERG blockade while simultaneously blocking inward Ca^2+^ (verapamil) and Na^+^ (ranolazine) ion channels ([@B30]). Mexiletine and diltiazem are low-proarrhythmic-risk drugs that do not prolong the QT at all. Recently, CiPA researchers proposed a new ECG biomarker, JTpeak, which may enable the identification of drugs producing false-positive results ([@B30]). Proarrhythmic drugs prolong the QT and the JTpeak due to hERG blockade, but not when the hERG blockade is offset by simultaneous blockade of other depolarizing ion channels (as by verapamil and ranolazine: only the QT prolonged but not the JTpeak). In this study, we explored the ability of the results of 3D ECG simulations to identify false-positive results independently of clinically obtained ECG data.

Materials and Methods
=====================

ECG Simulation Using Models of the Ventricles and Torso
-------------------------------------------------------

The model construction and ECG simulation are also described in our previous papers ([@B10]; [@B15]; [@B24]). Human ventricular geometry and torso were from our previous studies ([@B15]; [@B24]) ([Figures 1A--C](#F1){ref-type="fig"}). Human ventricular geometry was reconstructed from the computed tomography (CT) images obtained from the University of Ulsan Medical Center using a commercially available software Aquarius intuition (TeraRecon Inc., San Mateo, CA, United States). Tetrahedral mesh was generated inside the 3D ventricular model using an in-house software ([Figure 1A](#F1){ref-type="fig"}). The number of grid element was 1,475,818. For the modeling of Purkinje fibers, the 2-dimensional representation of the Purkinje network shown in the paper by [@B2] was digitized, scaled to the size of the 3D model, and mapped onto the endocardial surface of the 3D model of the ventricles ([Figure 1B](#F1){ref-type="fig"}). Pacing was applied at the location of His bundle. The model of Purkinje fibers simply transmits the electrical signal unidirectionally. The speeds of signal transmission at various regions were adjusted manually so that the simulated activation map matches that of clinical data ([@B6]; [Supplementary Figure S2](#TS2){ref-type="supplementary-material"}). The end nodes of the Purkinje network stimulated myocardium by applying stimulation current of −80.0 A/F until the membrane potential exceeds −10 mV. The endocardial nodes connected to the node nearest to each end node of the Purkinje network were considered the Purkinje-muscle junction (PMJ). All the tetrahedral elements containing the PMJ nodes were stimulated. Signal propagation from the stimulation nodes throughout the tissue was obtained by solving a reaction-diffusion equation (Eq. 1) numerically:

![Models of the ventricle and torso used in the present study. **(A)** Grid of the ventricular model. **(B)** Model of the Purkinje fiber network. **(C)** Model of the torso.](fphys-10-01139-g001){#F1}
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where *V*~m~ is the transmembrane potential, *t* is time, *D* is the diffusion tensor, *C*~m~ is the membrane capacitance, and *I*~ion~ and *I*~*stim*~ are ionic and stimulation currents, respectively. The equation was spatially discretized by using finite element and the time derivative was approximated by forward Euler method ([@B10]). To calculate *I*~ion~, the O'Hara-Rudy dynamic (ORd) human ventricular cell model was used ([@B20]). ORd model has three types of cells: endocardial, M, and epicardial cells. Each cell type was assigned to the ventricular wall with reference to the figure shown in the paper by [@B28]. We also tested three recently published optimized cell models ([@B16]; [@B7]; [@B12]). To calculate ECG values, the boundary element model of the human torso proposed by [@B22] was used ([Figure 1C](#F1){ref-type="fig"}). The ECG was calculated by computing the potentials on the torso surface using the following equation ([@B22]):
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where ϕ~*ek*~(*r*) is potential at a point r on surface k. $\sigma_{k}^{-}$ and $\sigma_{k}^{+}$ are the conductivity inside and outside the surface k, respectively, *J*~*c*~ is the source current density field, and *r*′ and *r*″ are variables. The summation is over all surfaces *l*. dΩ~*rr*″~ is the solid angle subtended at *r* by the infinitesimal surface element located at *r*″. The key parameters of simulation are shown in [Table 1](#T1){ref-type="table"}.

###### 

Key parameters of simulation.

  ------------------------------------------ -----------------
  Number of computational elements           1,475,818
  Ventricular tissue diffusion coefficient   0.00154 cm^2^/s
  Ventricular cell membrane capacitance      2.0 μF/cm^2^
  Body conductivity                          2.0 mS/cm
  ------------------------------------------ -----------------

Incorporation of the Effects of Drugs in the ECG Simulation
-----------------------------------------------------------

For the simulation of drug effect on ECG, we used the parameter values obtained by CiPA researchers to compare with their clinical data ([@B3]; [@B13], [@B14]). We tested seven drugs: dofetilide, bepridil, cisapride, verapamil, ranolazine, mexiletine, and diltiazem. The effects of drugs were incorporated in the ECG simulation by partly blocking the corresponding ion channels (*I*~Na~, *I*~NaL~, *I*~CaL~, and *I*~Kr~) in the ionic-current model. The percentage of blockage of each ionic current was calculated using the Hill equation ([@B8]). The Cmax, IC~50~, and Hill coefficient values for each drug with respect to each ionic current were adopted from the literature ([Table 2](#T2){ref-type="table"}) ([@B3]; [@B13], [@B14]). Cmax means free Cmax unless otherwise stated. The effects of each drug on single-cell action potentials \[of endocardial (endo), epicardial (epi), and mid-myocardial (M) cells\] were examined first, and 3D ECG simulations were performed at 1×, 5× and 10× Cmax.

###### 

Percentages of blockage of four ionic currents.

                      ***I*~NaL~**   ***I*~CaL~**   ***I*~Na~**   ***I*~Kr~(hERG)**
  ------------------- -------------- -------------- ------------- -------------------
  **Dofetilide**                                                  
  Cmax (μM)           0.002          0.002          0.002         0.002
  IC50 (μM)           126            44.5           1.36          0.001
  Hill coefficient    1.1            3.6            1.1           0.6
  Block at Cmax (%)   0.000526       2.24E-14       0.0765        60.2
  **Bepridil**                                                    
  Cmax (μM)           0.033          0.033          0.033         0.033
  IC50 (μM)           1.82           2.82           2.96          0.149
  Hill coefficient    1.4            0.65           1.2           0.9
  Block at Cmax (%)   0.363          5.26           0.452         20.5
  **Cisapride**                                                   
  Cmax (μM)           0.0026         0.0026         0.0026        0.0026
  IC50 (μM)           9260           1030           1790          0.012
  Hill coefficient    6.3            4.8            0.67          1.3
  Block at Cmax (%)   5.3E-40        1.35E-25       0.0123        12.0
  **Verapamil**                                                   
  Cmax (μM)           0.081          0.081          0.081         0.081
  IC50 (μM)           24.1           0.204          2590          0.499
  Hill coefficient    2              1.1            3.5           1.1
  Block at Cmax (%)   0.00113        26.6           1.71E-14      11.9
  **Ranolazine**                                                  
  Cmax (μM)           1.95           1.95           1.95          1.95
  IC50 (μM)           7.94           900            53.3          6.49
  Hill coefficient    0.95           3.9            1.9           0.8
  Block at Cmax (%)   20.8           4.06E-9        0.186         27.6
  **Mexiletine**                                                  
  Cmax (μM)           4.13           4.13           4.13          4.13
  IC50 (μM)           9.02           38.9           26.1          Infinity
  Hill coefficient    1.4            1              3.8           −
  Block at Cmax (%)   25.1           9.60           0.0905        0
  **Diltiazem**                                                   
  Cmax (μM)           0.122          0.122          0.122         0.122
  IC50 (μM)           21.6           0.113          36.9          6.57
  Hill coefficient    0.68           0.72           1.4           0.8
  Block at Cmax (%)   2.87           51.4           0.0336        3.96

The percentages were calculated using the Hill equation applying the Cmax, IC50, and Hill coefficient values adopted from the literatgure (

Crumb et al., 2016

;

Li et al., 2017

,

2019

). Cmax (free Cmax) values are from

Li et al. (2017)

. IC

50

and Hill coefficient values of hERG are from
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are from
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Results
=======

Effects on Single-Cell APs
--------------------------

[Figure 2](#F2){ref-type="fig"} shows AP curves for endocardial, M, and epicardial cells for seven drugs at Cmax values of 1×, 5×, and 10× ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). The Cmax values are listed in [Table 2](#T2){ref-type="table"}. The increases in the 90% AP duration (APD~90~) for the three drugs in endocardial, M, and epicardial cells compared with the no-drug control are shown in [Table 3](#T3){ref-type="table"}. Among the three drugs, dofetilide induced the greatest increase in the APD~90~ value, followed by ranolazine and verapamil. When Cmax was increased from 1× to 10×, APD~90~ increased for all three drugs and all three cell types, with the exception of M cells, in the presence of dofetilide. Dofetilide induced ventricular tachycardia in the M cells at Cmax values of 5× and 10× ([Figure 2](#F2){ref-type="fig"}). [Table 4](#T4){ref-type="table"} shows the transmural dispersion of repolarization (TDR) values, calculated as the difference between the largest and smallest APD~90~s among the endocardial, M, and epicardial cells. The TDR was largest in the case of dofetilide, and verapamil did not alter the TDR at a Cmax of 1× compared with the drug-free control ([Table 4](#T4){ref-type="table"}). At a Cmax of 10×, verapamil increased the APD~90~ of epicardial cells to a greater degree than that of M cells ([Table 3](#T3){ref-type="table"}), which resulted in a decreased TDR compared with the drug-free control ([Table 4](#T4){ref-type="table"}). [Figure 3](#F3){ref-type="fig"} shows AP curves for seven drugs with different cell electrophysiology models. The models of [@B20] and [@B7] provided relatively long ADP. Safe drugs resulted in relatively short APD except for ranolazine in which metabolites seem to play a significant role in drug binding ([@B18]).

![Effects on single-cell action potential. Action potential curves are shown for 7 drugs at Cmax values of 1×, 5×, and 10×. The action potentials of endocardial, M, and epicardial cells are shown for each drug and Cmax value. Dofetilide at Cmax values of 5× and 10× and cisapride at 10× induced tachycardia.](fphys-10-01139-g002){#F2}

###### 

Simulated ΔAPD~90~ for endocardial, M, and epicardial cells (Units: ms).

  **Drugs**    **1× Cmax**   **5× Cmax**   **10× Cmax**                                      
  ------------ ------------- ------------- -------------- ------ ------ ------ ------ ------ -----
  Dofetilide   157           182           136            277    --     239    341    --     288
  Bepridil     34            37            28             115    127    104    174    201    158
  Cisapride    21            21            17             124    138    108    225    --     194
  Verapamil    4             12            13             57     71     69     123    113    135
  Ranolazine   49            50            43             131    146    120    188    235    170
  Mexiletine   --13          --11          --7            --36   --29   --12   209    --14   5
  Diltiazem    --30          --14          --2            --29   --16   15     --18   --6    34

###### 

Simulated changes in TDR, QTc, and JT~peak~c according to drug concentration (Unit: ms).

  **Drugs**    **1× Cmax**   **5× Cmax**   **10× Cmax**                                    
  ------------ ------------- ------------- -------------- ------ ------ ----- ------ ----- -----
  Dofetilide   46            266           247            --     --     --    --     --    --
  Bepridil     9             51            44             23     179    179   43     289   281
  Cisapride    4             30            26             31     194    191   --     --    --
  Verapamil    0             17            18             2      79     83    --23   137   166
  Ranolazine   7             70            74             26     216    206   64     --    --
  Mexiletine   --4           --10          --9            --17   --     --    142    --    --
  Diltiazem    --12          --19          --20           --27   --30   --1   --27   --9   24

![Action potentials with different cell models. Action potential curves are shown for 7 drugs with 4 different cell models at 1× Cmax. Action potentials of endocardial, M, and epicardial cells are shown.](fphys-10-01139-g003){#F3}

Effects on 3D ECG Parameters
----------------------------

To examine the effects of drug concentration on ECG parameters, 3D ECG simulations were performed using the conditions shown in [Figure 2](#F2){ref-type="fig"}. [Figure 4](#F4){ref-type="fig"} shows the simulated ECGs (lead I) for the seven drugs according to concentration. Dofetilide resulted in the greatest increase in the ΔQTc value at 1× Cmax ([Table 4](#T4){ref-type="table"}). At a Cmax value of 5×, dofetilide induced ventricular flutter; at 10× Cmax, dofetilide, cisapride, and ranolazine induced ventricular flutter. In contrast to findings reported by the CiPA researchers ([@B30]), the JT~peakC~ value increased with the QTc value for ranolazine and verapamil ([Table 4](#T4){ref-type="table"}). [Figure 5](#F5){ref-type="fig"} shows ECGs obtained from using different optimized cell models for the seven drugs at 1× Cmax. Dofetilide exhibited relatively long QT interval in all the cell models except for the model of [@B12] in which the ECG morphology was irregular. The amplitude of the T wave was largest in the case of [@B7] while the model of [@B16] exhibited the smallest T wave amplitude. [Table 5](#T5){ref-type="table"} shows JT~peak~c prolongation of drugs for different optimized cell models. The optimized cell models resulted in JT~peak~c prolongations which are more consistent with clinical observations than the original ORd model. For ranolazine, metabolites seem to play a significant role in drug binding ([@B18]).

![Effects on body-surface ECG parameters. Body-surface ECG data (lead I) are shown for 7 drugs at Cmax values of 1×, 5×, and 10× compared with drug-free conditions. The QT interval was longest for dofetilide.](fphys-10-01139-g004){#F4}

###### 

Simulated ΔJT~peak~c for various drugs with different cell models (Unit: ms).

  **Drugs**    **[@B20]**   **[@B16]**   **[@B7]**   **[@B12]**
  ------------ ------------ ------------ ----------- ------------
  Dofetilide   247          67           142         127
  Bepridil     44           13           35          49
  Cisapride    26           7            21          8
  Verapamil    18           1            12          5
  Ranolazine   74           32           43          58
  Mexiletine   --9          --5          --14        --6
  Diltiazem    --20         --15         --16        --4

![ECGs with different cell models. Body-surface ECGs (lead I) are shown for 7 drugs applying different cell models at 1× Cmax. Irregular morphology of ECG is observed for dofetilide in the case of the model by [@B12].](fphys-10-01139-g005){#F5}

Because dofetilide induced ventricular tachycardia in the single-cell model at Cmax values of 5× and 10×, ventricular tachycardia was examined in the 3D model. [Figure 6](#F6){ref-type="fig"} shows the AP from the single-cell model, the AP at a point in the 3D model, and ECG data from the 3D model in the presence of dofetilide at a Cmax of 10×, which indicates the presence of ventricular tachycardia. [Figure 6](#F6){ref-type="fig"} also shows snapshots of ventricular AP propagation, which exhibits rotational activation. [Table 6](#T6){ref-type="table"} lists the occurrences of ventricular tachycardia caused by the three drugs according to concentration. The arrhythmia morphology was not polymorphic, which is a limitation of our model.

![Drug-induced ventricular tachycardia. The action potential from the single-cell model, action potential at a point in the 3D model, and ECG data from the 3D model in the presence of dofetilide at a Cmax value of 10× are shown. Photographs of ventricular action potential propagation are also shown.](fphys-10-01139-g006){#F6}

###### 

Occurrence of ventricular tachycardia. Simulated ECG was examined to determine the occurrence of VT (O: VT occurred, X: VT did not occur).

               **1× Cmax**   **5× Cmax**   **10× Cmax**
  ------------ ------------- ------------- --------------
  Dofetilide   X             O             O
  Bepridil     X             X             X
  Cisapride    X             X             O
  Verapamil    X             X             X
  Ranolazine   X             X             O
  Mexiletine   X             X             X
  Diltiazem    X             X             X

To test the suitability of the models to examine JT~peak~, we checked the rate dependence of JT~peak~ using various models without any drug effect. All the models showed decreasing JT~peak~ as heart rate increased with the model of [@B7] exhibiting the best agreement with clinical data ([@B11]; [Figure 7](#F7){ref-type="fig"}). We also validated intercellular conduction by comparing activation times obtained from our ventricular model with those in the literature ([Supplementary Figure S1](#TS2){ref-type="supplementary-material"}).

![Rate dependence of JTpeak. JTpeak was obtained for different heart rates with different cell models. Simulation results were compared with clinical data by [@B11].](fphys-10-01139-g007){#F7}

Discussion
==========

In evaluations of drug safety, the QT interval in ECGs has received much attention because drug-induced prolongation of the QT interval is, under certain conditions, associated with the risk of TdP, a fatal ventricular arrhythmia. However, prolongation of the QT interval does not always lead to TdP. The recently proposed CiPA initiative aims to enable more comprehensive evaluation of drug safety ([@B30]; [@B31]). In this study, we examined the effects of seven drugs on the QT interval using a realistic *in silico* 3D body-surface ECG model that included the ventricles and torso. Among the seven drugs, dofetilide resulted in the greatest increase in the QT interval, which is consistent with published data ([@B29]). Dofetilide use entails a relatively high risk of TdP ([@B27]). However, the occurrence of TdP requires not only prolongation of the QT interval, but also early afterdepolarization (EAD) and TDR ([@B1]). In this study, dofetilide also exhibited the highest TDR values ([Figure 2](#F2){ref-type="fig"} and [Table 4](#T4){ref-type="table"}). In addition, dofetilide does not block the *I*~NaL~ and *I*~CaL~ channels ([Table 2](#T2){ref-type="table"}), which increases the probability of EAD. The increases in APD~90~ caused by ranolazine and verapamil were smaller than those induced by dofetilide, which resulted in smaller increases in the QT interval in the 3D ECG simulation. Ranolazine blocks *I*~NaL~ channels almost as effectively as *I*~Kr~ channels ([Table 2](#T2){ref-type="table"}) and entails a low risk of TdP because blockade of *I*~NaL~ channels decreases the risk of EAD ([@B9]). Interestingly, for ranolazine, the magnitude of the increase in the APD~90~ was similar in endocardial and M cells, whereas for verapamil it was similar in M and epicardial cells, at 1× Cmax ([Table 3](#T3){ref-type="table"}). Dofetilide induced the greatest increase in the APD~90~ of M cells; most QT interval-prolonging drugs increase the APD of M cells preferentially, thereby increasing the TDR value ([@B1]). Verapamil did not affect the TDR at a Cmax of 1× and decreased it at 10× Cmax, consistent with the low risk of TdP associated with its use ([@B17]).

In this study, the increases in JT~peakC~ were similar to those in QTc, in contrast to the finding of [@B29] that the JT~peakC~ is not increased by ranolazine or verapamil at a Cmax value of 1×. T~peak~ corresponds to the time of epicardial repolarization, and most drugs that increase the epicardial APD also increase the JT~peakC~ because of delayed epicardial layer repolarization. Ranolazine and verapamil increased the epicardial APD and the JT~peakC~ in our simulation. Thus, the discrepancy in the JT~peakC~ interval between our simulated results and human ECGs performed after administration of verapamil or ranolazine implies that the 3D model needs further improvement. In order to make the model accurately predict the prolongations of JT~peak~ and T~peak~--T~end~, the improvement of the cell models seems to be needed. If epicardial APD remains the same, and endocardial APD increases under the effects of a drug, JTpeak should remain the same, and T~peak~--T~end~ should increase, which is expected in the cases of safe drugs. The current cell models do not exhibit these behaviors of APD changes under the effects of safe drugs, which disqualifies the current model as a biomarker. EAD was also observed in our simulated AP for ranolazine at a Cmax value of 10×, but not 5×. This result may reflect a limitation of the *in vitro* data-based simulation, in which the role of metabolites was not considered. However, simulation at a Cmax value of 10× was not recommended by the CiPA because of excessive variability in the values of the markers at higher concentrations ([@B14]). Thus, the ventricular tachycardia induced by dofetilide (but not by verapamil or ranolazine) at 5× Cmax may have potential as an *in silico* biomarker for screening of the TdP risks posed by candidate molecules.

Although validation is needed to improve the predictive capability of the model, this study demonstrated the possibility of the model to become an effective biomarker to examine the effects of drugs on body-surface ECG parameters using realistic 3D models of the ventricles and torso. This step could lead to our ultimate goal of creating a comprehensive *in silico* drug-safety testing system.

This study also has several limitations. First, in the human ventricular model, we had difficulty in defining the spatial distribution of the sandwiched midcardial cell layer between the endocardial and epicardial cells. The distribution was adopted from the scheme presented in [@B28]. Second, in the model of the ventricles and torso, we did not consider the lungs and other tissues between the body surface and the heart when solving for the body surface potentials. The bone located between the heart and body surface might influence ECG data due to its much higher electrical impedance than that of body fluids. We did not consider the effect of this bone in the ECG algorithm. In a future study, the electrical impedance of bone will be considered. Similarly, the effects of non-homogeneous properties of extracellular tissue should be incorporated into the heart model. However, we believe that these limitations did not greatly affect the major findings of this study.
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AP

:   action potential

CT

:   computed tomography

EAD

:   early afterdepolarization

ECG

:   electrocardiogram

ORd

:   O'Hara-Rudy dynamic

TdP

:   Torsades de pointes

TDR

:   transmural dispersion of repolarization.
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